Live Event Coverage
The latest news and dealmakers from global life science partnering events
Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD
Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Spea
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir
Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health
Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development.
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli
Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017
An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,
Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception
With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia
Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America
As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio
Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology
Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProN
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?
Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...
Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery
Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi
Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity
Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML
Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic hea
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta
Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in add
Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals
Speaking at the 2017 Biotech Showcase™ in San Francisco, Gruenenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017
As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and...
Unmet needs, uncommon commitment: The shift toward investment in rare diseases
Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...
Digital Medicine Showcase 2017: State of the Digital Medicine Industry
Tools that will usher in a new age of healthcare are changing the game by creating more effective R&D processes, strengthening the patient-physician relationship, and simultaneously enabling individua
#DigMedShow & #MedtechShow 2017: Verily, Qualcomm, Proteus, Johnson & Johnson, Hogan Lovells
A holistic approach is critical to creating viable solutions for an efficient and effective healthcare system. With representatives across several key sectors, this panel examines the impact of non-tr
Biotech Showcase™ 2017: Journalist Wrap: Biotech 2017: Pulse, prognosis and the press
As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and beyo
Digital Medicine Showcase 2017: Fireside Chat with Bryan Roberts
Gain insights from one of the industry’s most successful investors, featured on the Forbes Midas list eight times running (2008–2016).